Literature DB >> 19572290

Cyclic alphavbeta6-targeting peptide selected from biopanning with clinical potential for head and neck squamous cell carcinoma.

Jenn-Ren Hsiao1, Yao Chang, Yuh-Ling Chen, Su-Huei Hsieh, Keng-Fu Hsu, Chun-Fu Wang, Sen-Tien Tsai, Ying-Tai Jin.   

Abstract

BACKGROUND: A cyclic peptide-displaying phage library was used for biopanning on oral squamous cell carcinoma (OSCC) cells to identify cancer-targeting peptides. This study was designed to characterize the receptor specificity of a candidate phage clone/peptide (phage/peptide-29) and to explore the clinical potential of this peptide.
METHODS: Immunofluorescent confocal microscopy, phage binding assay, and immunohistochemical studies were used to demonstrate the receptor specificity of phage/peptide-29. The effect of peptide-29 on the proliferation of OSCC cells was studied using 3-dimensional (3D) cell cultures.
RESULTS: Phage/peptide-29 preferentially binds integrin alphavbeta6 rather than other alphav-associated integrins. Peptide-29 significantly inhibits the proliferation of OSCC cells in 3D cell cultures. On human pathological sections, phage-29 targets oral cancer cells in a alphavbeta6-dependent manner. Besides, we showed that integrin alphavbeta6 is universally (94.7%, 36/38) expressed in all major kinds of head and neck squamous cell carcinomas (HNSCC).
CONCLUSIONS: Peptide-29 selected from biopanning may have clinical potential for HNSCC. Copyright 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19572290     DOI: 10.1002/hed.21166

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  14 in total

Review 1.  Peptide-mediated cancer targeting of nanoconjugates.

Authors:  Sumita Raha; Tatjana Paunesku; Gayle Woloschak
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-11-02

2.  Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma.

Authors:  Sven H Hausner; Richard J Bold; Lina Y Cheuy; Helen K Chew; Megan E Daly; Ryan A Davis; Cameron C Foster; Edward J Kim; Julie L Sutcliffe
Journal:  Clin Cancer Res       Date:  2018-11-06       Impact factor: 12.531

Review 3.  Molecular imaging of integrin αvβ6 expression in living subjects.

Authors:  Hao Liu; Yue Wu; Fan Wang; Zhaofei Liu
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

4.  The Effect of Bi-Terminal PEGylation of an Integrin αvβ₆-Targeted ¹⁸F Peptide on Pharmacokinetics and Tumor Uptake.

Authors:  Sven H Hausner; Nadine Bauer; Lina Y Hu; Leah M Knight; Julie L Sutcliffe
Journal:  J Nucl Med       Date:  2015-03-26       Impact factor: 10.057

5.  Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer.

Authors:  Richard H Kimura; Robert Teed; Benjamin J Hackel; Marybeth A Pysz; Courtney Z Chuang; Ataya Sathirachinda; Jürgen K Willmann; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2011-12-15       Impact factor: 12.531

6.  Identification of HN-1-Peptide Target in Head and Neck Squamous Cell Carcinoma Cells.

Authors:  Jozsef Dudas; Christin Idler; Georg Sprinzl; Andreas Bernkop-Schnuerch; Herbert Riechelmann
Journal:  ISRN Oncol       Date:  2011-05-03

Review 7.  Tumor Targeting via Integrin Ligands.

Authors:  Udaya Kiran Marelli; Florian Rechenmacher; Tariq Rashad Ali Sobahi; Carlos Mas-Moruno; Horst Kessler
Journal:  Front Oncol       Date:  2013-08-30       Impact factor: 6.244

Review 8.  RGD-Binding Integrins in Head and Neck Cancers.

Authors:  Hanadi Talal Ahmedah; Laurence H Patterson; Steven D Shnyder; Helen M Sheldrake
Journal:  Cancers (Basel)       Date:  2017-05-26       Impact factor: 6.639

9.  Targeted Delivery of Cell Penetrating Peptide Virus-like Nanoparticles to Skin Cancer Cells.

Authors:  Bee Koon Gan; Chean Yeah Yong; Kok Lian Ho; Abdul Rahman Omar; Noorjahan Banu Alitheen; Wen Siang Tan
Journal:  Sci Rep       Date:  2018-05-31       Impact factor: 4.379

10.  99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.

Authors:  Xiaohua Zhu; Jinbo Li; Yeongjin Hong; Richard H Kimura; Xiaowei Ma; Hongguang Liu; Chunxia Qin; Xiang Hu; Thomas R Hayes; Paul Benny; Sanjiv Sam Gambhir; Zhen Cheng
Journal:  Mol Pharm       Date:  2014-02-24       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.